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ABSTRACT  
There has been an increasing trend in the number of prescribed and over-the-counter drug recall over the last few 
years. The recall is usually due to company's discovery, customer's complaint or Food and Drug Administration 
(FDA) observation. The process of recall involves a planned specific course of action, which addresses the depth of 
recall, need for public warning, and the extent of effectiveness checks for the recall. The FDA review and/or 
recommend changes to the firm's recall strategy, as appropriate. The critical recall information list includes the 
identity of the product; summary of the failure; amount of product produced in the distribution chain and direct 
account. Product recalls clashes thousands of companies every year affecting: sales, testing customer relationships 
and disrupting supply chains. Drug recall is incubus for pharmaceutical companies. It effects the reputation of the 
company. The reason for the recall can be divided into two categories: manufacturing related and safety/efficacy 
related. It is essential to follow all the guidelines related to drug development and manufacturing procedure to 
minimize drug recall. 
Keywords: Drug product recall, guidelines, process, recall information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISSN: 2456-8058                                                         CODEN (USA): UJPRA3                                                                 54 
              Universal Journal of Pharmaceutical Research 
           www.ujpr.org 
                                                 Review Article            Volume 1, Issue 2, 2016 
 
 
 
 
 
 
 
Viney Chawla*
1
, Manish Pal Singh
1
 and Manish Kumar
2
 
Rajiv Academy for Pharmacy
1
, Chattikara, Mathura, Uttar Pradesh, India. 
MM College of Pharmacy
2
, Maharishi Markandeshwar University, Mullana, Ambala, 
Haryana India. 
Corresponding author:  Email: drvineychawla@gmail.com 
DOI: http://doi.org/10.22270/ujpr.v1i2.RW2 
 
                   Article received on- 19 October    Revised on- 26 December   Accepted on- 30 December 2016 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The pharmaceutical industry is at an important 
crossroads in medical innovations, which develop 
cures for health conditions. Without this industry, 
many therapies would not be introduced to the 
market, and many health problems would remain 
unsolved.  
 
 
 
The pharmaceutical industry has traditionally been 
very profitable, and the global market had annual 
growth prediction of 5 to 8%
1,2
.  Yet amidst the 
massive increase in the field, factors like product 
returns and recalls are giving the companies new 
challenges, such as litigation problems, negative 
publicity, loss of patent protection for many major 
drugs and widespread efforts to contain drug 
spending
3
.
 
On the other hand, increased 
competitiveness, fast-changing structure of 
competitors, complex strategic positioning, 
shrinking pipelines, counterfeit drugs  
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and a fight for global market share are adding 
more burdens to the growth of the industry
4,5
. 
For a detailed introduction on this topic readers are 
advised to see the first part of this review
6
. In this 
previous part published in this journal we have 
discussed issues like Lack of sterility assurance, 
Presence of particulate matter and 
container/closure problems. In this second part, the 
focus will be on unapproved new drugs, Presence 
of undeclared therapeutically active moiety, 
microbial contamination and some other 
miscellaneous reasons. 
ISSUES RELATED TO PRODUCT RECALL 
I. Unapproved New Drug 
The FDA's evidence-based system of drug 
approval and the OTC monograph system play 
essential roles in ensuring that drugs are both safe 
and effective. For instance, during the drug 
approval process the applicant must demonstrate 
that its manufacturing processes can reliably 
produce drug products of expected identity, 
strength, quality, and purity. The manufacturers of 
unapproved drug products have not received FDA 
approval and do not conform to a monograph for 
making over-the-counter (OTC) drugs. The lack of 
evidence demonstrating that these unapproved 
drugs are safe and effective is a significant public 
health concern (Table 1)
7
. Unapproved drugs 
are not generic medications, and neither their 
safety nor their efficacy can be assured
8
.
  
In 2013, 
retail pharmacies in US filled over three billion 
prescriptions. These prescriptions, as well as those 
prescriptions administered directly by healthcare 
professionals, were intended to treat or prevent 
myriad conditions and diseases, because 
physicians can lawfully prescribe FDA-approved  
 
 
 
 
products for any purpose, including uses 
unapproved by FDA, if the physician believes such 
use would benefit the patient. Because almost all 
prescription medicines have side effects and 
contraindications, including some serious and fatal 
side effects, it is essential that healthcare 
professionals have access to timely, accurate and 
comprehensive information about the medicines 
they prescribe
9,10
. 
II. Presence of Undeclared Therapeutically 
Active Moiety 
Falsified and substandard drugs may contain toxic 
ingredients; some of the most compelling stories of 
pharmaceutical crime are of frank poisoning. By 
far the more common problem however, is 
medicine that simply does not work. Medications 
for chronic and infectious diseases alike have been 
found falsified and substandard. Data from the 
FDA office of criminal investigation indicate that 
pills and tablets are the most commonly 
compromised products they investigate, mostly 
produced by individual criminals, not negligent 
businesses
11
. The WHO is developing a system for 
the global surveillance and monitoring of falsified 
and substandard drugs. Different regulatory 
authorities have different, often widely divergent, 
requirements. To complicate the problem, many 
small regulatory authorities lack the technical 
depth to evaluate the bioequivalence data generics 
manufacturers submit (Table 2)
12
.  
III. Microbial Contamination 
One of the most important areas in pharmaceutical 
process control is the development of systems to 
control the number, survival, and proliferation of 
microorganisms during manufacturing of non-
sterile and sterile pharmaceutical products  
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(Table 3). In relation to this general profile, 
commonly considered four main sources of 
microbial contaminations are clean room air, 
personnel, surfaces and water. An earlier study, 
pointed out that maintaining the integrity of a 
pharmaceutical production environment of clean 
room is a constant battle
13,14
. Most common 
microorganisms in clean rooms are gram-positive 
bacteria. These microorganisms often have a close 
phylogenetic affiliation as indicated by 
comparative analysis of partial 16S rDNA studies, 
such as between the Micrococci and 
Staphylococci
15
. In addition, there are, in fewer 
numbers, certain fungi associated with clean 
rooms. Clean room microflora is predominantly of 
gram-positive bacteria. With the genera 
Staphylococcus and Micrococcus, many of the 
species are indigenous to humans. Although Gram-
positive microorganisms are ubiquitous in clean 
rooms and make up the overwhelming majority of 
isolates
16
.  
IV. Miscellaneous Reasons  
The information about counterfeit medicines is 
everywhere press reports
17
, WHO fact sheets 
18
,
 
FDA press releases
19
, U.S. government task 
forces
20
, law review articles
21
, medical journals
22 
and international trade associations
23
. One widely–
cited “fact” attributed to the WHO is the claim that 
counterfeit medicines make up more than 10% of 
today’s global medicines available in the market 
(Table 4)
24
. Yet another statistic is that in 
developing countries, up to 25% of the medicines 
used are counterfeit or substandard 
25
. Publicly 
discussing counterfeiting is an important tool to 
enforce the industry’s price discrimination 
structures across borders, enhancing overall 
industry profits 
26
.  
 
 
 
CONCLUSION 
The authors have tried to exhaustively review the 
reasons behind drug product recall in two parts of 
this article. Drug Product Recall as a whole brings 
bad name to the company but is essential in the 
larger interest of society. However, through careful 
handling, manufacturing, packaging and 
transportation, such incidences may be kept to a 
minimum. An aptitude for no mistakes at every 
level of organization may help achieve this goal 
easily. 
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Table 1: Unapproved new drug 
S. N. Date Product Description Reasons/ Problems Company 
1. 11/04/2016 Super Herbs Capsules, 
Weight Loss Dietary 
Supplement 
Unapproved new drug- FDA laboratory 
testing found SUPER HERBS to contain 
sibutramine, desmethylsi butramine, and/or 
phenolphthalein. 
Super Herbs 
2. 09/01/2016 Dietary Supplement Unapproved new drug R Thomas 
Marketing LLC 
3. 18/12/2015 Dietary Supplement Unapproved new drug SmartLipo365 
4. 11/12/2015 Dietary Supplement Unapproved new drug (undeclared 
hydroxythiohomosildenafil, an analogue of 
sildenafil) 
Reesna Inc., 
5. 09//12/2015 Dietary Supplement Unapproved new drug (Undeclared 
diclofenac) 
Lucy's Weight Loss 
System 
6. 03/12/2015 Dietary Supplement Unapproved new drug Lipo Escultura 
7. 11/09/2015 Miracle 30 and Miracle 
Rock 48 dietary 
supplements 
Unapproved new drug The One Minute 
Miracle Inc. 
8. 24/08/2015 Dietary Supplements These products contain the undeclared drug 
ingredient salicylic acid making these 
unapproved new drugs 
Novacare, LLC 
9. 23/12/2013 Dietary Supplement Unapproved new drug Deseo Rebajar Inc. 
10. 29/11/2013 Dietary Supplement Unapproved new drug IQ Formulations 
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Table 2: Presence of Undeclared Therapeutically Active Moiety 
S. N. Date Product Description Reasons/ Problems Company 
1. 10/05/2016 Marketed as a dietary 
supplement 
Products contain sildenafil, and analogs 
of sildenafil 
SOS Telecom, 
Inc. 
2. 05/04/2016 Marketed as a dietary 
supplement 
Contains ligandrol Invisiblu 
International LLC 
3. 28/01/2016 Pink Bikini and Shorts on 
The Beach 
Undeclared sibutramine, 
phenolphthalein  
Lucy's Weight 
Loss System 
4. 20/01/2016 licorice Coughing Liquid Contains undeclared morphine Master Herbs, Inc. 
5. 23/12/2015 Dietary Supplement Undeclared sibutramine and 
phenolphthalein 
Bee Xtreme LLC 
6. 25/11/2015 Compounded Multivitamins Contains high amounts of Vitamin D3 Glades Drugs 
7. 28/10/2015 Dietary Supplement Undeclared Active Pharmaceutical 
Ingredients 
Premiere Sales 
Group 
8. 25/09/2015 Capsules intended for male 
sexual enhancement 
Undeclared desmethyl carbondenafil 
and dapoxetine 
TF Supplements 
9. 23/09/2015 Pink Bikini and Shorts on 
The Beach 
Undeclared Sibutramine and 
Phenolphthalein 
Lucy's Weight 
Loss System 
10. 24/08/2015 Dietary Supplements These products contain the undeclared 
drug ingredient salicylic acid making 
these unapproved new drugs 
Novacare, LLC 
12. 12/06/2015 Advanced Joint Formula 
capsules 
Undeclared diclofenac and 
chlorpheniramine 
GandC Natural 
13. 03/06/2015 Smart Lipo (800, 900, 950 
mg) capsules 
Undeclared sibutramine, 
desmethylsibutramine, and 
phenolphthalein. 
SmartLipo365 
14. 19/12/2014 Dietary supplement capsules 
used for weight loss 
Undeclared Drug Ingredient Bethel Nutritional 
Consulting, Inc. 
15. 19/12/2014 Dietary supplement capsules 
used for weight loss 
Undeclared Drug Ingredient Bethel Nutritional 
Consulting, Inc. 
16. 12/12/2014 Dietary supplement capsules 
used for body building and 
weight loss 
Undeclared Synthetic 
hormone/prohormone Ingredient 
Wyked Labs 
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Table 3: Microbial contamination 
S. N. Date Product Description Reasons/ Problems Company 
1. 31/12/2014 Ribavirin powder for solution Microbial Contamination Valeant Pharmaceuticals 
North America LLC 
2. 18/12/2013 Sterile injectable medications Potential for microbial 
contamination 
Abrams Royal Pharmacy 
                                                                                                                      
Table 4: Miscellaneous/ Other 
S. N. Date Product Description Reasons/ Problems Company 
1. 01/03/2016 fluconazole Injection, USP, (in 0.9% sodium 
chloride) 200 mg per 100mL 
Discovery of an out of specification 
impurity result detected 
Sagent 
Pharmaceuticals
, Inc. 
2. 16/02/2016 morphine sulfate 0.5 mg/mL preservative 
free in 0.9% sodium chloride 
Super-potent Pharmakon 
Pharmaceuticals 
3. 31/12/2015 norepinephrine bitartrate added to sodium 
chloride 
Discoloration Phar MED 
Diuem 
4. 30/10/2015 epinephrine Injection, USP (0.15 mg and 0.3 
mg) 
Potential Inaccurate Dosage Delivery Sanofi US 
5. 09/10/2015 Over the counter acetaminophen Tablets. The acetaminophen Tablets, 500 mg is 
incorrectly labeled as 325 mg Tablets. 
Medline 
Industries, Inc. 
6. 13/07/2015 calcium chloride Intravenous Infusion 10% 
in 10 mL prefilled glass syringes 
Incompatibility between syringe and 
needleless adapters 
Mylan 
Institutional 
LLC 
7. 12/12/2014 Combination of omeprazole and misoprostol 
in a paste 
Not approved for use as an animal drug Tristar Equine 
Marketing, 
LLC. 
8. 27/11/2013 Blood glucose test strips May produce erroneously low blood 
glucose results 
Abbott 
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